SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity
Abstract The protective effect of neutralizing antibodies in SARS-CoV-2 infected individuals is not yet well defined. To address this issue, we have analyzed the kinetics of neutralizing antibody responses and their association with disease severity. Between March and May 2020, the prospective KING...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/7da6a66a461c490cb6ea008c28fd4f31 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:7da6a66a461c490cb6ea008c28fd4f31 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:7da6a66a461c490cb6ea008c28fd4f312021-12-02T10:48:13ZSARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity10.1038/s41598-021-81862-92045-2322https://doaj.org/article/7da6a66a461c490cb6ea008c28fd4f312021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-81862-9https://doaj.org/toc/2045-2322Abstract The protective effect of neutralizing antibodies in SARS-CoV-2 infected individuals is not yet well defined. To address this issue, we have analyzed the kinetics of neutralizing antibody responses and their association with disease severity. Between March and May 2020, the prospective KING study enrolled 72 COVID-19+ participants grouped according to disease severity. SARS-CoV-2 infection was diagnosed by serological and virological tests. Plasma neutralizing responses were assessed against replicative virus and pseudoviral particles. Multiple regression and non-parametric tests were used to analyze dependence of parameters. The magnitude of neutralizing titers significantly increased with disease severity. Hospitalized individuals developed higher titers compared to mild-symptomatic and asymptomatic individuals, which together showed titers below the detection limit in 50% of cases. Longitudinal analysis confirmed the strong differences in neutralizing titers between non-hospitalized and hospitalized participants and showed rapid kinetics of appearance of neutralizing antibodies (50% and 80% of maximal activity reached after 11 and 17 days after symptoms onset, respectively) in hospitalized patients. No significant impact of age, gender or treatment on the neutralizing titers was observed in this limited cohort. These data identify a clear association of humoral immunity with disease severity and point to immune mechanisms other than antibodies as relevant players in COVID-19 protection.Benjamin TrinitéFerran Tarrés-FreixasJordi RodonEdwards PradenasVíctor UrreaSilvia MarfilMaría Luisa Rodríguez de la ConcepciónCarlos Ávila-NietoCarmen Aguilar-GurrieriAna BarajasRaquel OrtizRoger ParedesLourdes MateuAlfonso ValenciaVíctor GuallarLidia RuizEulàlia GrauMarta MassanellaJordi PuigAnna ChamorroNuria Izquierdo-UserosJoaquim SegalésBonaventura ClotetJorge CarrilloJúlia Vergara-AlertJulià BlancoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Benjamin Trinité Ferran Tarrés-Freixas Jordi Rodon Edwards Pradenas Víctor Urrea Silvia Marfil María Luisa Rodríguez de la Concepción Carlos Ávila-Nieto Carmen Aguilar-Gurrieri Ana Barajas Raquel Ortiz Roger Paredes Lourdes Mateu Alfonso Valencia Víctor Guallar Lidia Ruiz Eulàlia Grau Marta Massanella Jordi Puig Anna Chamorro Nuria Izquierdo-Useros Joaquim Segalés Bonaventura Clotet Jorge Carrillo Júlia Vergara-Alert Julià Blanco SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity |
| description |
Abstract The protective effect of neutralizing antibodies in SARS-CoV-2 infected individuals is not yet well defined. To address this issue, we have analyzed the kinetics of neutralizing antibody responses and their association with disease severity. Between March and May 2020, the prospective KING study enrolled 72 COVID-19+ participants grouped according to disease severity. SARS-CoV-2 infection was diagnosed by serological and virological tests. Plasma neutralizing responses were assessed against replicative virus and pseudoviral particles. Multiple regression and non-parametric tests were used to analyze dependence of parameters. The magnitude of neutralizing titers significantly increased with disease severity. Hospitalized individuals developed higher titers compared to mild-symptomatic and asymptomatic individuals, which together showed titers below the detection limit in 50% of cases. Longitudinal analysis confirmed the strong differences in neutralizing titers between non-hospitalized and hospitalized participants and showed rapid kinetics of appearance of neutralizing antibodies (50% and 80% of maximal activity reached after 11 and 17 days after symptoms onset, respectively) in hospitalized patients. No significant impact of age, gender or treatment on the neutralizing titers was observed in this limited cohort. These data identify a clear association of humoral immunity with disease severity and point to immune mechanisms other than antibodies as relevant players in COVID-19 protection. |
| format |
article |
| author |
Benjamin Trinité Ferran Tarrés-Freixas Jordi Rodon Edwards Pradenas Víctor Urrea Silvia Marfil María Luisa Rodríguez de la Concepción Carlos Ávila-Nieto Carmen Aguilar-Gurrieri Ana Barajas Raquel Ortiz Roger Paredes Lourdes Mateu Alfonso Valencia Víctor Guallar Lidia Ruiz Eulàlia Grau Marta Massanella Jordi Puig Anna Chamorro Nuria Izquierdo-Useros Joaquim Segalés Bonaventura Clotet Jorge Carrillo Júlia Vergara-Alert Julià Blanco |
| author_facet |
Benjamin Trinité Ferran Tarrés-Freixas Jordi Rodon Edwards Pradenas Víctor Urrea Silvia Marfil María Luisa Rodríguez de la Concepción Carlos Ávila-Nieto Carmen Aguilar-Gurrieri Ana Barajas Raquel Ortiz Roger Paredes Lourdes Mateu Alfonso Valencia Víctor Guallar Lidia Ruiz Eulàlia Grau Marta Massanella Jordi Puig Anna Chamorro Nuria Izquierdo-Useros Joaquim Segalés Bonaventura Clotet Jorge Carrillo Júlia Vergara-Alert Julià Blanco |
| author_sort |
Benjamin Trinité |
| title |
SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity |
| title_short |
SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity |
| title_full |
SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity |
| title_fullStr |
SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity |
| title_full_unstemmed |
SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity |
| title_sort |
sars-cov-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/7da6a66a461c490cb6ea008c28fd4f31 |
| work_keys_str_mv |
AT benjamintrinite sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT ferrantarresfreixas sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT jordirodon sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT edwardspradenas sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT victorurrea sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT silviamarfil sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT marialuisarodriguezdelaconcepcion sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT carlosavilanieto sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT carmenaguilargurrieri sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT anabarajas sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT raquelortiz sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT rogerparedes sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT lourdesmateu sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT alfonsovalencia sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT victorguallar sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT lidiaruiz sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT eulaliagrau sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT martamassanella sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT jordipuig sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT annachamorro sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT nuriaizquierdouseros sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT joaquimsegales sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT bonaventuraclotet sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT jorgecarrillo sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT juliavergaraalert sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity AT juliablanco sarscov2infectionelicitsarapidneutralizingantibodyresponsethatcorrelateswithdiseaseseverity |
| _version_ |
1718396658130092032 |